This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 10/23/2026 at 8:15 am EEST.
Nightingale Health announced on Thursday that it had signed an agreement with the British general practice, The Private GP Group. As part of the agreement, Nightingale's blood analysis will be incorporated into the group's annual health assessments. The news is a continuation of several smaller agreements announced recently. While the value of each individual agreement is likely small, together, they provide good support for our growth estimates.
Going forward, The Private GP Group will offer the test to its patients in the areas its clinics serve in Surrey and South London. The group's health assessments already include a blood test, from which Nightingale determines the 10-year risks for five common chronic diseases. In our view, the model in which Nightingale's test is integrated directly into standard sampling and the existing care pathway is at the core of the company's value creation and competitive advantage. Although the volume generated by a single small chain of general practices does not yet solve the company’s long-term growth challenges, successful implementation can serve as a strong reference for winning new, larger clients in the United Kingdom. Regarding the investment story, however, our main focus remains on how the volumes of the group’s largest international partnerships scale.
This content is only available for logged in users